Company profile
Novo Nordisk
Diversified pharma / diabetes & obesity
Share price · NVO
$45.71+1.43 (+3.23%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(26 total)
26Total Assets
9Approved
8Phase 3 / Filed
9Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
insulin aspart(NovoLog / Fiasp) | Approved | Insulin receptor (basal)Peptide | Type 2 Diabetes |
insulin degludec(Tresiba) | Approved | Insulin receptor (basal)Peptide | Type 2 Diabetes |
insulin detemir(Levemir) | Approved | Insulin receptor (basal)Peptide | Type 2 Diabetes |
insulin icodec(Awiqli) | Approved | Insulin receptor (basal)Peptide | Type 2 Diabetes |
liraglutide(Saxenda / Victoza) | Approved | GLP-1 receptorPeptide | ObesityType 2 DiabetesAtherosclerotic Cardiovascular Disease |
Nedosiran(Rivfloza) | Approved | LDHA (lactate dehydrogenase A) mRNASmall molecule | Chronic Kidney Disease |
| Approved | GLP-1 receptorPeptide | Type 2 Diabetes | |
repaglinide(Prandin / NovoNorm) | Approved | SUR1 (short-acting)Small molecule | Type 2 Diabetes |
semaglutide(Wegovy / Ozempic / Rybelsus) | Approved | GLP-1 receptorPeptide | ObesityType 2 DiabetesChronic Kidney DiseaseAtherosclerotic Cardiovascular DiseaseMASH / NASH |
| Phase 3 | GLP-1 receptor · Amylin receptorPeptide | ObesityType 2 Diabetes | |
| Phase 3 | Amylin receptor · Amylin/calcitonin receptor (dual)Peptide | ObesityType 2 DiabetesChronic Kidney Disease | |
cagrilintide/semaglutide(CagriSema) | Phase 3 | Amylin receptor · GLP-1 receptorPeptide | ObesityType 2 Diabetes |
| Phase 3 | Transthyretin (TTR)Monoclonal antibody | Heart Failure | |
| Phase 3 | Insulin receptor (basal) · GLP-1 receptorPeptide | Type 2 Diabetes | |
| Phase 3 | GLP-1/GIP/glucagon receptor (triple)Peptide | ObesityChronic Kidney Disease |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.